相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study
Yoshihiko Tomita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
Takashi Sakaguchi et al.
Oncotarget (2018)
Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
Elisa Oricchio et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
Zuquan Xiong et al.
ONCOTARGET (2017)
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma
Hirofumi Yoshino et al.
CANCER RESEARCH (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Vanessa S. Rodrik-Outmezguine et al.
NATURE (2016)
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives
S. C. Joosten et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2015)
The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines
Irem Dogan Turacli et al.
TUMOR BIOLOGY (2015)
The structural basis for mTOR function
Domagoj Baretic et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2014)
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J. Garcia-Donas et al.
ANNALS OF ONCOLOGY (2013)
The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro
Qiang Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
Kurt G. Pike et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
mTOR kinase inhibitors as potential cancer therapeutic drugs
Shi-Yong Sun
CANCER LETTERS (2013)
Differentiating mTOR inhibitors in renal cell carcinoma
Sumanta K. Pal et al.
CANCER TREATMENT REVIEWS (2013)
A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
Hao Zhang et al.
PLOS ONE (2013)
Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR
Takeshi Chiyomaru et al.
PLOS ONE (2013)
Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene
Jing Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells
Peter B. Makhov et al.
MOLECULAR CANCER THERAPEUTICS (2012)
International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma
Vitaly Margulis et al.
EUROPEAN UROLOGY (2011)
The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (Publication with Expression of Concern. See vol. 25, pg. 4194, 2019)
Daniel C. Cho et al.
CLINICAL CANCER RESEARCH (2010)
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Kathryn G. Foster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new
Kyle A. Furge et al.
LANCET ONCOLOGY (2010)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
mTOR mediates human trophoblast invasion through regulation of matrix-remodeling enzymes and is associated with serine phosphorylation of STAT3
Susann Busch et al.
EXPERIMENTAL CELL RESEARCH (2009)
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
Jing-song Chen et al.
HEPATOLOGY RESEARCH (2009)
CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) Complex
Daniel Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Temsirolimus, an inhibitor of mammalian target of rapamycin
Brian I. Rini
CLINICAL CANCER RESEARCH (2008)
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Alfredo Toschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The PTEN-PI3K pathway: of feedbacks and cross-talks
A. Carracedo et al.
ONCOGENE (2008)
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Thomas E. Hutson et al.
ONCOLOGIST (2008)
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Andrew Y. Choo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Emilie Vander Haar et al.
NATURE CELL BIOLOGY (2007)
Hypoxia-inducible factors: central regulators of the tumor phenotype
John D. Gordan et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal
Cheol-Hee Choi
CANCER CELL INTERNATIONAL (2005)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth
K Kondo et al.
PLOS BIOLOGY (2003)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
JK Maranchie et al.
CANCER CELL (2002)
分享论文
